These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 31454463)

  • 1. Changes in plasma circulating microvesicles in patients with HCV-related cirrhosis after treatment with direct-acting antivirals.
    Campello E; Radu CM; Zanetto A; Bulato C; Shalaby S; Spiezia L; Franceschet E; Burra P; Russo FP; Simioni P
    Liver Int; 2020 Apr; 40(4):913-920. PubMed ID: 31454463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals.
    Russo FP; Zanetto A; Campello E; Bulato C; Shalaby S; Spiezia L; Gavasso S; Franceschet E; Radu C; Senzolo M; Burra P; Lisman T; Simioni P
    Liver Int; 2018 Dec; 38(12):2210-2218. PubMed ID: 29738632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of direct-acting antivirals on platelet-associated immunoglobulin G and thrombocytopenia in hepatitis C virus-related chronic liver disease.
    Honma Y; Shibata M; Hayashi T; Kusanaga M; Ogino N; Minami S; Kumei S; Oe S; Miyagawa K; Senju M; Matsuoka H; Watanabe T; Hiura M; Abe S; Harada M
    Liver Int; 2019 Sep; 39(9):1641-1651. PubMed ID: 31009141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.
    Kang Q; Xu J; Luo H; Tan N; Chen H; Cheng R; Pan J; Han Y; Yang Y; Liu D; Xi H; Yu M; Xu X
    J Viral Hepat; 2021 Sep; 28(9):1284-1292. PubMed ID: 34105867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis.
    Abd Alla MDA; El Awady MK; Dawood RM; Elhawary MA; Al-Azhari SS; Galal AGM
    Arch Virol; 2018 Oct; 163(10):2765-2774. PubMed ID: 29971486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort.
    Kondili LA; Zanetto A; Quaranta MG; Ferrigno L; Panetta V; Calvaruso V; Zignego AL; Brunetto MR; Raimondo G; Biliotti E; Ieluzzi D; Iannone A; Madonia S; Chemello L; Cavalletto L; Coppola C; Morisco F; Barbaro F; Licata A; Federico A; Cerini F; Persico M; Pompili M; Ciancio A; Piscaglia F; Chessa L; Giacometti A; Invernizzi P; Brancaccio G; Benedetti A; Baiocchi L; Gentile I; Coppola N; Nardone G; Craxì A; Russo FP;
    United European Gastroenterol J; 2024 Apr; 12(3):352-363. PubMed ID: 38032175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does fibrosis really regress in HIV/hepatitis C virus co-infected patients after treatment with direct antiviral agents?
    Rial-Crestelo D; Sepúlveda MA; González-Gasca FJ; Geijo-Martínez P; Martínez-Alfaro E; Barberá JR; Yzusqui M; Casallo S; García M; Hornero CM; Espinosa-Gimeno A; Torralba M
    AIDS; 2020 Mar; 34(3):427-432. PubMed ID: 31996593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
    Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
    J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment.
    Stasi C; Sadalla S; Carradori E; Monti M; Petraccia L; Madia F; Gragnani L; Zignego AL
    Curr Med Res Opin; 2020 Feb; 36(2):245-249. PubMed ID: 31702411
    [No Abstract]   [Full Text] [Related]  

  • 11. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
    Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
    BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
    Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
    Carrat F; Fontaine H; Dorival C; Simony M; Diallo A; Hezode C; De Ledinghen V; Larrey D; Haour G; Bronowicki JP; Zoulim F; Asselah T; Marcellin P; Thabut D; Leroy V; Tran A; Habersetzer F; Samuel D; Guyader D; Chazouilleres O; Mathurin P; Metivier S; Alric L; Riachi G; Gournay J; Abergel A; Cales P; Ganne N; Loustaud-Ratti V; D'Alteroche L; Causse X; Geist C; Minello A; Rosa I; Gelu-Simeon M; Portal I; Raffi F; Bourliere M; Pol S;
    Lancet; 2019 Apr; 393(10179):1453-1464. PubMed ID: 30765123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.
    Kozbial K; Moser S; Al-Zoairy R; Schwarzer R; Datz C; Stauber R; Laferl H; Strasser M; Beinhardt S; Stättermayer AF; Gschwantler M; Zoller H; Maieron A; Graziadei I; Trauner M; Steindl-Munda P; Hofer H; Ferenci P
    Liver Int; 2018 Jun; 38(6):1028-1035. PubMed ID: 29136329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy.
    Huang R; Rao HY; Yang M; Gao YH; Wang J; Jin Q; Ma DL; Wei L
    World J Gastroenterol; 2021 Feb; 27(5):404-415. PubMed ID: 33584072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver cT
    Jayaswal ANA; Levick C; Collier J; Tunnicliffe EM; Kelly MD; Neubauer S; Barnes E; Pavlides M
    Abdom Radiol (NY); 2021 May; 46(5):1947-1957. PubMed ID: 33247768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals.
    Ravaioli F; Conti F; Brillanti S; Andreone P; Mazzella G; Buonfiglioli F; Serio I; Verrucchi G; Bacchi Reggiani ML; Colli A; Marasco G; Colecchia A; Festi D
    Dig Liver Dis; 2018 Jun; 50(6):573-579. PubMed ID: 29567413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of platelet in thrombocytopenic HCV patients after treatment with direct-acting antiviral agents and its relation to outcome.
    Soliman Z; El Kassas M; Elsharkawy A; Elbadry M; Hamada Y; ElHusseiny R; M El-Nahaas S; Fouad R; Esmat G; Abdel Alem S
    Platelets; 2021 Apr; 32(3):383-390. PubMed ID: 32250721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
    Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.